Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma

Manuel C Maia; Paulo Bergerot; Sumanta K Pal

doi:10.1016/j.euf.2017.02.008

Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma

Eur Urol Focus. 2016 Dec 15;2(6):579-581. doi: 10.1016/j.euf.2017.02.008. Epub 2017 Mar 1.

Authors

Manuel C Maia¹, Paulo Bergerot¹, Sumanta K Pal²

Affiliations

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
² Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: [email protected].

PMID: 28723488
DOI: 10.1016/j.euf.2017.02.008

Abstract

First-line systemic therapy for patients with metastatic renal cell carcinoma should largely entail the use of targeted agents. Depending on the clinical factors, VEGF- or mTOR-directed agents may be appropriate.